{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-198411","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.375698+00:00","generated_at":"2026-05-31T10:05:27.301250+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial","bullets":["100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.","Received FDA guidance for registrational trial of INB-100 in AML; IND submission planned Q1 2025.","INB-200 for GBM shows prolonged survival in higher dose cohorts; one MGMT-unmethylated patient in remission >1 year.","No new relapses since May 15, 2024; safety manageable with no significant cell therapy-related toxicities.","INB-400 Phase 2 trial for front-line GBM actively enrolling at multiple US sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-198411","json":"https://secwatch.observer/filing/0001193125-24-198411.json","markdown":"https://secwatch.observer/filing/0001193125-24-198411.md","text":"https://secwatch.observer/filing/0001193125-24-198411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/0001193125-24-198411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/d801512d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:27.301250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}